What ferroptosis is — and why it matters now
Ferroptosis is a form of regulated, non-apoptotic cell death driven by iron-dependent lipid peroxidation, formally named in 2012 and now documented across more than 60 retrieved literature records as morphologically and biochemically distinct from apoptosis, necroptosis, and autophagy. Three hallmarks define it: accumulation of intracellular labile iron (Fe²⁺); iron-catalyzed peroxidation of polyunsaturated fatty acids (PUFAs), particularly arachidonoyl-containing phospholipids; and collapse of the glutathione (GSH)/glutathione peroxidase 4 (GPX4) antioxidant axis.
The field sits at the intersection of two major unmet medical needs. In oncology, cancer cells that acquire resistance to apoptosis-inducing chemotherapies, targeted therapies, and immunotherapies frequently retain or upregulate sensitivity to ferroptosis — making it a mechanistically orthogonal route around the most common resistance mechanisms. In neurodegeneration, the same iron-lipid peroxidation cascade drives neuronal loss in Alzheimer’s disease (AD), Parkinson’s disease (PD), Huntington’s disease (HD), amyotrophic lateral sclerosis (ALS), stroke, and traumatic brain injury — but here the therapeutic objective is the inverse: inhibiting ferroptosis to protect neurons.
Unlike apoptosis — which depends on caspase activation and produces characteristic DNA laddering — ferroptosis is driven entirely by iron-catalyzed lipid ROS accumulation and does not require caspase activity. This distinction means cancer cells that have silenced apoptotic pathways (a common resistance mechanism) may remain fully susceptible to ferroptotic death.
The research landscape is overwhelmingly academic at this stage. No patent filings were identified in the retrieved dataset, which skews heavily toward peer-reviewed literature. The dominant contributors are Chinese academic medical centers and universities, supplemented by European and North American research institutions including Stanford University, Memorial Sloan Kettering Cancer Center, the University of Cologne, and the Helmholtz Center Munich.
The five molecular nodes that control ferroptotic sensitivity
Five principal molecular targets govern whether a cell undergoes or resists ferroptosis, and each represents a distinct pharmacological handle for either inducing cell death in tumors or blocking it in neurons.
GPX4 — the central bottleneck
GPX4 (glutathione peroxidase 4) is the most consistently cited molecular target across retrieved results. It converts lipid hydroperoxides to non-toxic lipid alcohols using GSH as reductant; its inhibition or GSH depletion is the central mechanistic bottleneck of ferroptosis. Critically, therapy-resistant cancer cells — including those resistant to targeted EGFR or KRAS therapies — maintain GPX4-dependent survival, making them selectively vulnerable to GPX4 inhibition.
GPX4 (glutathione peroxidase 4) is the most consistently cited ferroptosis molecular target; therapy-resistant cancer cells that survive EGFR or KRAS inhibition maintain GPX4-dependent survival, making them selectively vulnerable to GPX4 inhibitors such as RSL3.
System Xc− (SLC7A11/SLC3A2) — the cystine gateway
The cystine/glutamate antiporter imports extracellular cystine for intracellular GSH synthesis. Inhibition by erastin, sulfasalazine, or sorafenib starves GPX4 of its GSH cofactor. SLC7A11 overexpression has been identified as a resistance mechanism in multiple tumor types, and NRF2 activity — which drives SLC7A11 transcription — functions as a biomarker of erastin resistance.
FSP1 / CoQ10 — the parallel resistance axis
FSP1 (ferroptosis suppressor protein 1, also known as AIFM2) is a GPX4-independent ferroptosis suppressor that regenerates coenzyme Q10 (CoQ10/ubiquinol), which functions as a lipophilic radical-trapping antioxidant. FSP1 is described in both oncology and Parkinson’s disease contexts as a parallel protective axis — meaning tumors can resist ferroptosis even when GPX4 is inhibited if FSP1 remains active.
NRF2 and p53 — transcriptional regulators with context-dependent roles
NRF2, the master antioxidant transcription factor, regulates ferroptosis resistance by controlling expression of SLC7A11, ferritin, and other antioxidant genes. NFE2L1, a related transcription factor, was shown to protect cells from ferroptosis by maintaining proteasomal function. p53 plays a complex, context-dependent role: wild-type p53 can promote ferroptosis by repressing SLC7A11 transcription and driving ROS production, but in colorectal cancer it can antagonize ferroptosis via DPP4 complex formation. Post-translational modifications of p53 are identified as pharmacological targets for modulating this axis.
Iron metabolism regulators: transferrin, ferritin, DMT1
Ferroptosis sensitivity is tightly linked to the labile iron pool, controlled by transferrin receptor 1 (TfR1) for iron uptake, ferritin for storage, and ferroportin for export. The enzyme ACSL4 (acyl-CoA synthetase long-chain family member 4) incorporates arachidonic acid into phospholipids, generating the PUFA-phospholipid substrates for ferroptotic peroxidation. ACSL4 upregulation sensitizes cells to ferroptosis; its suppression confers resistance — a finding from Dalian University (2022) that has implications for patient stratification.
ACSL4 (acyl-CoA synthetase long-chain family member 4) is the key enzyme that incorporates arachidonic acid into phospholipids to generate the PUFA-phospholipid substrates for ferroptotic peroxidation; ACSL4 upregulation sensitizes cells to ferroptosis while its suppression confers resistance.
Map the full ferroptosis target landscape — GPX4, FSP1, SLC7A11 — with live patent and literature data.
Explore ferroptosis data in PatSnap Eureka →Six therapeutic modalities targeting iron-dependent cell death
Ferroptosis research has produced six distinct therapeutic modality classes, each with a different mechanistic entry point and development stage. All remain predominantly preclinical in the retrieved dataset.
1. Small-molecule ferroptosis inducers (Class 1 and Class 2)
Class 1 inducers are system Xc− inhibitors. Erastin and its analogues inhibit SLC7A11, depleting intracellular cysteine and GSH and starving GPX4 of its cofactor. Sulfasalazine and sorafenib — both already FDA-approved for other indications — are identified as Class 1 inducers. RAS-mutant cancer cell lines (fibrosarcoma, NSCLC, PDAC) show heightened erastin sensitivity via synthetic lethality, according to research from Tokyo Medical and Dental University (2021).
Class 2 inducers are direct GPX4 inhibitors. RSL3 bypasses cystine transport and directly inactivates the lipid hydroperoxide-reducing enzyme, killing cancer cells in culture and tumor xenografts. Artesunate (an artemisinin derivative) is also highlighted as a ferroptosis-inducing drug already in clinical use for other indications.
2. Iron chelators as ferroptosis inhibitors (neuroprotective)
In neurodegenerative disease applications, iron chelators — deferiprone and deferoxamine — inhibit ferroptosis by sequestering the labile Fe²⁺ pool required for Fenton chemistry and lipid peroxide propagation. This is the inverse therapeutic objective from oncology. Deferiprone already has clinical use in iron-overload conditions; retrieved results from Chang Gung University (2022) discuss its repurposing potential in Parkinson’s disease.
3. Lipophilic antioxidants and ROS scavengers
Ferrostatin-1 and liproxstatin-1 are the benchmark small-molecule inhibitors of ferroptosis, preventing lipid ROS accumulation in brain, kidney, and cardiac cell death models — characterized at Stanford University (2016). Mitochondria-targeted nitroxide compounds (XJB-5-131, JP4-039) were identified by the University of Pittsburgh (2016) as potent ferroptosis suppressors via intramitochondrial lipid peroxidation blockade. Both classes are preclinical.
4. Nanomedicine-based ferroptosis delivery systems
Emerging results from 2022–2023 describe Fenton-reaction-active iron oxide nanoparticles, lipid-nanoparticle carriers, and nanoenzymes as vehicles to amplify intratumoral ROS selectively. These approaches enable combination of ferroptosis with chemotherapy, radiotherapy, and immunotherapy, and are described as concentrating ferroptotic stimuli intratumorally while sparing normal tissue. Stage: largely preclinical, exclusively academic literature.
5. Genetic modulation of ferroptosis regulators
Gene-level interventions target SLC7A11, GPX4, FSP1, NRF2, and p53 via siRNA, CRISPR screening, or overexpression studies. Prominin2 (PROM2) — a ferroptosis resistance gene induced by the lipid peroxidation product 4-hydroxynonenal (4HNE) via the p38 MAPK → HSF1 → PROM2 axis — was shown by the University of Massachusetts Medical School (2021) to be suppressible via HSF1 inhibitors, re-sensitizing resistant cells to erastin and RSL3. Mitochondrial ferritin (FtMt) overexpression protected neuronal cells from erastin-induced ferroptosis in research from Hebei Normal University (2016).
6. Natural products and repurposed agents
Food-derived active ingredients and traditional compounds are noted as ferroptosis modulators in research from China Agricultural University (2022) and China Pharmaceutical University (2022). MicroRNAs that post-transcriptionally control GPX4, SLC7A11, and iron metabolism genes offer an additional oligonucleotide-based intervention layer. Both areas are at early preclinical stage with academic-only literature.
Ferroptosis inducers in drug-resistant cancers: evidence and limits
Cancer cells that acquire resistance to apoptosis-inducing therapies frequently retain or upregulate sensitivity to ferroptosis — and the evidence base spans seven distinct cancer types, all at the preclinical stage.
The cancers with identified ferroptotic vulnerability in the retrieved dataset are: hepatocellular carcinoma (HCC), pancreatic ductal adenocarcinoma (PDAC), glioblastoma, non-small cell lung cancer (NSCLC), diffuse large B-cell lymphoma (DLBCL), multiple myeloma, and ovarian cancer. According to research from Nanjing Medical University (2022) and the Affiliated Haikou Hospital of Xiangya Medical College (2022), these cancer types share a common feature: resistance to conventional apoptotic death pathways has not simultaneously conferred resistance to ferroptotic induction.
“Cancer cells acquiring resistance to apoptosis-inducing chemotherapies, targeted therapies, and immunotherapies frequently retain or upregulate sensitivity to ferroptosis — offering a mechanistically orthogonal route around the most common resistance mechanisms.”
In PDAC specifically, research from the University of Liège (2022) identified myoferlin — an oncoprotein controlling mitochondrial structure — as a targetable node in KRAS-mutant tumors. WJ460-mediated myoferlin targeting triggered mitophagy and ferroptosis by reducing xc−/GPX4 abundance, suggesting that KRAS-mutant PDAC, one of the most treatment-resistant cancers, may be approachable via this axis. Research from WIPO-tracked innovation categories confirms PDAC as a high-unmet-need area attracting novel mechanism exploration.
In glioma, retrieved results from the First Affiliated Hospital of China Medical University (2022) note that patients develop chemotherapy resistance during treatment and that ferroptosis induction is being explored to overcome this. No phase I/II trial data were present in the retrieved dataset for any of these tumor types.
Cancer stem cells (CSCs) — which are highly resistant to apoptosis and conventional therapy — may be switchable to ferroptotic death via intracellular iron accumulation, according to research from Quevedo State Technical University (2022). This is a significant translational signal: CSCs are widely believed to drive tumor relapse and metastasis, and their resistance to standard apoptotic therapies has been a major obstacle in oncology.
The immunogenic dimension of ferroptosis adds further translational relevance. Research from INSERM/Cordeliers Research Centre (2020) describes ferroptotic cells as immunogenic — emitting damage-associated molecular patterns (DAMPs) that stimulate dendritic cell maturation and can vaccinate against fibrosarcoma rechallenge in preclinical models. This positions ferroptosis not merely as a cell-killing mechanism but as a potential immunotherapy primer, consistent with the broader understanding of immunogenic cell death tracked by institutions such as Nature-published immunology research.
Ferroptotic cancer cells emit damage-associated molecular patterns (DAMPs) that stimulate dendritic cell maturation and can vaccinate against fibrosarcoma tumor rechallenge in preclinical models, establishing ferroptosis as a form of immunogenic cell death with potential to enhance immunotherapy responses.
Identify which cancer types have the strongest ferroptosis inducer evidence base — search the full literature in PatSnap Eureka.
Search ferroptosis cancer literature in PatSnap Eureka →Combination strategies and emerging directions
Retrieved results from 2021–2023 converge on four combination strategies that may amplify ferroptosis’s therapeutic impact beyond what single-agent induction can achieve.
Ferroptosis + checkpoint immunotherapy (PD-1/PD-L1)
Tumor-infiltrating T cells may induce ferroptosis in cancer cells via IFN-γ-mediated SLC7A11 suppression. Immunotherapy monotherapy efficacy rates — described as below 30% — may be enhanced by ferroptosis co-activation. Research from Charité Universitätsmedizin Berlin (2022) specifically examined this combination in hepatocellular carcinoma, while broader immunotherapy combination signals come from multiple 2022 records. According to NIH-supported research frameworks, combination approaches targeting orthogonal cell death mechanisms represent a priority area in immuno-oncology.
Ferroptosis + radiotherapy
Radiotherapy generates ROS and releases iron, functioning as a natural ferroptosis potentiator. Combining radiotherapy with dedicated ferroptosis inducers is proposed as a strategy to enhance radiosensitivity in radioresistant tumors, as described in research from Peking Union Medical College (2022). Separately, gemcitabine and platinum compounds are noted as inducing ferroptotic death as part of their mechanism of action, suggesting ferroptosis already contributes to currently used clinical treatments.
Nanomedicine + ferroptosis amplification
Iron-based nanocatalytic systems — Fenton-active nanoparticles, liposomal delivery of erastin or RSL3 — are described as enabling concentration of ferroptotic stimuli intratumorally while sparing normal tissue. Research from Qingdao University (2023) describes this as one of the most active emerging directions in the field, with the potential to address the tissue-selectivity problem that currently limits systemic ferroptosis induction.
MicroRNA modulation
A regulatory layer where specific microRNAs post-transcriptionally control GPX4, SLC7A11, and iron metabolism genes offers oligonucleotide-based intervention possibilities. This is at the earliest preclinical stage but represents a mechanistically distinct approach to modulating ferroptotic sensitivity without direct enzyme inhibition — an approach that WHO innovation tracking frameworks categorize as an emerging RNA therapeutic modality.
The translational gap: where the pipeline stands today
Despite significant preclinical evidence, no dedicated ferroptosis inducer has yet reached clinical practice. A 2022 clinical pharmacology review from University Hospital Schleswig-Holstein explicitly characterizes the path from basic science to clinic as “rocky,” identifying three unresolved barriers: biomarker identification for patient selection, tissue selectivity to avoid off-target ferroptosis in healthy tissue, and in vivo pharmacokinetics of purpose-designed inducers.
“No dedicated ferroptosis inducer has yet reached clinical practice — biomarker identification, tissue selectivity, and in vivo pharmacokinetics remain unresolved as of the reviewed dataset.” — University Hospital Schleswig-Holstein, 2022
The translational landscape has two immediately actionable elements. First, sorafenib (approved for HCC and renal cell carcinoma) and sulfasalazine (approved for inflammatory bowel disease and rheumatoid arthritis) are FDA-approved drugs that induce ferroptosis as part of their mechanism — providing immediate clinical relevance without the need for new drug approval. Second, deferiprone and deferoxamine — iron chelators with established clinical use in iron-overload conditions — have preclinical data supporting ferroptosis inhibition in Parkinson’s disease, offering a repurposing path for the neuroprotective indication.
The research geography matters for understanding where the next translational signals are likely to emerge. The retrieved dataset is dominated by Chinese academic medical centers — Central South University (Xiangya Hospital), Sichuan University (West China Schools), Zhejiang University, Sun Yat-sen University, and the Chinese Academy of Sciences — with significant contributions from North American institutions (Memorial Sloan Kettering Cancer Center, Stanford University, University of Massachusetts Medical School, The Wistar Institute) and European centers (University of Cologne CECAD, Helmholtz Center Munich, Philipps-Universität Marburg, University of Liège, INSERM/Cordeliers Research Centre). The absence of patent filings in the retrieved dataset suggests the field has not yet moved substantially from academic publication to IP protection — a signal that the commercialization window may still be open for organizations with drug discovery capabilities. Patent landscape analysis via PatSnap’s drug discovery intelligence platform can help identify where IP activity is beginning to emerge around ferroptosis targets.
As of the reviewed dataset (predominantly 2016–2023 literature), no dedicated ferroptosis inducer has reached clinical practice; the translational barriers identified are biomarker identification for patient selection, tissue selectivity, and in vivo pharmacokinetics of purpose-designed ferroptosis-inducing compounds.
The field’s trajectory — from formal naming in 2012 to more than 60 retrieved literature records spanning seven cancer types and six neurodegenerative conditions — represents one of the most rapid expansions in regulated cell death biology. Organizations tracking this space through PatSnap’s life sciences intelligence tools will be positioned to identify the earliest IP and clinical signals as the field moves toward its first purpose-designed clinical candidates.